Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles

References

• Abdel-Rahman, M. H., R. Pilarski, C. M. Cebulla, J. B. Massengill, B. N. Christopher, G. Boru, P. Hovland, and F. H. Davidorf. 2011. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. Journal of Medical Genetics 48:856–59. doi:10.1136/jmedgenet-2011-100156
   PubMed Web of Science ®Google Scholar
• Abdullayev, E., and Y. Lvov. 2011. Halloysite clay nanotubes for controlled release of protective agents. Journal of Nanoscience and Nanotechnology 11:10007–26. doi:10.1166/jnn.2011.5724
   PubMed Web of Science ®Google Scholar
• Agudo, A., C. A. Gonzalez, M. J. Bleda, J. Ramirez, S. Hernandez, F. Lopez, A. Calleja, R. Panades, D. Turuguet, A. Escolar, M. Beltran, and J. E. Gonzalez-Moya. 2000. Occupation and risk of malignant pleural mesothelioma: A case-control study in Spain. American Journal of Industrial Medicine 37:159–68. doi:10.1002/(SICI)1097-0274(200002)37:2<159::AID-AJIM1>3.0.CO;2-0
   PubMed Web of Science ®Google Scholar
• Aguilar-Madrid, G., E. Robles-Perez, C. A. Juarez-Perez, I. Alvarado-Cabrero, F. G. Rico-Mendez, and K. G. Javier. 2010. Case-control study of pleural mesothelioma in workers with social security in Mexico. American Journal of Industrial Medicine 53:241–51.
   PubMed Web of Science ®Google Scholar
• Altomare, D. A., C. W. Menges, J. Xu, J. Pei, L. Zhang, A. Tadevosyan, E. Neumann-Domer, Z. Liu, M. Carbone, I. Chudoba, A. J. Klein-Szanto, and J. R. Testa. 2011. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS ONE 6:e18828. doi:10.1371/journal.pone.0018828
   PubMed Web of Science ®Google Scholar
• Andersen, M., M. Grauslund, J. Ravn, J. B. Sorensen, C. B. Andersen, and E. Santoni-Rugiu. 2014. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma. The Journal of Molecular Diagnostics 16:418–30. doi:10.1016/j.jmoldx.2014.03.002
   PubMed Web of Science ®Google Scholar
• Andrici, J., A. Sheen, L. Sioson, K. Wardell, A. Clarkson, N. Watson, M. S. Ahadi, M. Farzin, C. W. Toon, and A. J. Gill. 2015. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Modern Pathology 28:1360–68. doi:10.1038/modpathol.2015.87
   PubMed Web of Science ®Google Scholar
• Antao, V. C., T. C. Larson, and D. K. Horton. 2012. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Current Opinion in Pulmonary Medicine 18:161–67. doi:10.1097/MCP.0b013e32834e897d
   PubMed Web of Science ®Google Scholar
• Arzt, L., F. Quehenberger, I. Halbwedl, T. Mairinger, and H. H. Popper. 2014. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathology Oncology Research 20:145–51. doi:10.1007/s12253-013-9677-2
   PubMed Web of Science ®Google Scholar
• Aschberger, K., H. J. Johnston, V. Stone, R. J. Aitken, S. M. Hankin, S. A. Peters, C. L. Tran, and F. M. Christensen. 2010. Review of carbon nanotubes toxicity and exposure—Appraisal of human health risk assessment based on open literature. Critical Reviews in Toxicology 40:759–90. doi:10.3109/10408444.2010.506638
   PubMed Web of Science ®Google Scholar
• Aust, A., P. M. Cook, and R. F. Dodson. 2011. Morphological and chemical mehanisms of elongated particle toxicities. Journal of Toxicology and Environmental Health, Part B 14:40–75. doi:10.1080/10937404.2011.556046
   PubMed Web of Science ®Google Scholar
• Bang, K. M., J. M. Mazurek, J. M. Wood, and S. A. Hendricks. 2014. Diseases attributable to asbestos exposure: Years of potential life lost, United States, 1999–2010. American Journal of Industrial Medicine 57:38–48. doi:10.1002/ajim.v57.1
   PubMed Web of Science ®Google Scholar
• Baumann, F., B. J. Buck, R. V. Metcalf, B. T. McLaurin, D. J. Merkler, and M. Carbone. 2015a. The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from southern Nevada. Journal of Thoracic Oncology 10:731–37. doi:10.1097/JTO.0000000000000506
   PubMed Web of Science ®Google Scholar
• Baumann, F., E. Flores, A. Napolitano, S. Kanodia, E. Taioli, H. Pass, H. Yang, and M. Carbone. 2015b. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36:76–81. doi:10.1093/carcin/bgu227
   PubMed Web of Science ®Google Scholar
• Baumann, F., P. Maurizot, M. Mangeas, J. P. Ambrosi, J. Douwes, and B. Robineau. 2011. Pleural mesothelioma in New Caledonia: Associations with environmental risk factors. Environmental Health Perspectives 119:695–700. doi:10.1289/ehp.1002862
   PubMed Web of Science ®Google Scholar
• Below, J. E., N. J. Cox, N. K. Fukagawa, A. Hirvonen, and J. R. Testa. 2011. Factors that impact susceptibility to fiber-induced health effects. Journal of Toxicology and Environmental Health, Part B 14:246–66. doi:10.1080/10937404.2011.556052
   PubMed Web of Science ®Google Scholar
• Betti, M., E. Casalone, D. Ferrante, A. Romanelli, F. Grosso, S. Guarrera, L. Righi, S. Vatrano, G. Pelosi, R. Libener, D. Mirabelli, R. Boldorini, C. Casadio, M. Papotti, G. Matullo, C. Magnani, and I. Dianzani. 2015. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer 54:51–62. doi:10.1002/gcc.v54.1
   PubMed Web of Science ®Google Scholar
• Biggeri, A., R. Pasetto, S. Belli, C. Bruno, G. Di Maria, M. Mastrantonio, S. Trinca, R. Uccelli, and P. Comba. 2004. Mortality from chronic obstructive pulmonary disease and pleural mesothelioma in an area contaminated by natural fiber (fluoro-edenite). Scandinavian Journal of Work, Environment & Health 30:249–52. doi:10.5271/sjweh.786
   PubMed Web of Science ®Google Scholar
• Boffetta, P., K. Donaldson, S. Moolgavkar, and J. S. Mandel. 2014. A systematic review of occupational exposure to synthetic vitreous fibers and mesothelioma. Critical Reviews in Toxicology 44:436–49. doi:10.3109/10408444.2014.899558
   PubMed Web of Science ®Google Scholar
• Borczuk, A. C., J. Pei, R. N. Taub, B. Levy, O. Nahum, J. Chen, K. Chen, and J. R. Testa. 2016. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biology & Therapy 17:328–35.
   PubMed Web of Science ®Google Scholar
• Bott, M., M. Brevet, B. S. Taylor, S. Shimizu, T. Ito, L. Wang, J. Creaney, R. A. Lake, M. F. Zakowski, B. Reva, C. Sander, R. Delsite, S. Powell, Q. Zhou, R. Shen, A. Olshen, V. Rusch, and M. Ladanyi. 2011. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nature Genetics 43:668–72. doi:10.1038/ng.855
   PubMed Web of Science ®Google Scholar
• Boulanger, G., P. Andujar, J. C. Pairon, M. A. Billon-Galland, C. Dion, P. Dumortier, P. Brochard, A. Sobaszek, P. Bartsch, C. Paris, and M. C. Jaurand. 2014. Quantification of short and long asbestos fibers to assess asbestos exposure: A review of fiber size toxicity. Environmental Health 13:59. doi:10.1186/1476-069X-13-59
   PubMed Web of Science ®Google Scholar
• Bruno, C., R. Tumino, L. Fazzo, G. Cascone, A. Cernigliaro, M. De Santis, M. C. Giurdanella, C. Nicita, P. C. Rollo, S. Scondotto, E. Spata, A. Zona, and P. Comba. 2014. Incidence of pleural mesothelioma in a community exposed to fibres with fluoro-edenitic composition in Biancavilla (Sicily, Italy). Annali dell’istituto Superiore di Sanita 50:111–18.
   PubMed Web of Science ®Google Scholar
• Bueno, R., E. W. Stawiski, L. D. Goldstein, S. Durinck, A. De Rienzo, Z. Modrusan, F. Gnad, T. T. Nguyen, B. S. Jaiswal, L. R. Chirieac, D. Sciaranghella, N. Dao, C. E. Gustafson, K. J. Munir, J. A. Hackney, A. Chaudhuri, R. Gupta, J. Guillory, K. Toy, C. Ha, Y. J. Chen, J. Stinson, S. Chaudhuri, N. Zhang, T. D. Wu, D. J. Sugarbaker, F. J. De Sauvage, W. G. Richards, and S. Seshagiri. 2016. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics. 48:407–16.
   PubMed Web of Science ®Google Scholar
• Bunderson-Schelvan, M., J. C. Pfau, R. Crouch, and A. Holian. 2011. Nonpulmonary outcomes of asbestos exposure. Journal of Toxicology and Environmental Health, Part B 14:122–52. doi:10.1080/10937404.2011.556048
   PubMed Web of Science ®Google Scholar
• Camargo, M. C., L. T. Stayner, K. Straif, M. Reina, U. Al-Alem, P. A. Demers, and P. J. Landrigan. 2011. Occupational exposure to asbestos and ovarian cancer: A meta-analysis. Environmental Health Perspectives 119:1211–17. doi:10.1289/ehp.1003283
   PubMed Web of Science ®Google Scholar
• Camiade, E., C. Gramond, M. A. Jutand, S. Audignon, M. Rinaldo, E. Imbernon, D. Luce, F. Galateau-Salle, P. Astoul, J. C. Pairon, P. Brochard, and A. Lacourt. 2013. Characterization of a French series of female cases of mesothelioma. American Journal of Industrial Medicine 56:1307–16.
   PubMed Web of Science ®Google Scholar
• Carbone, M., Y. I. Baris, P. Bertino, B. Brass, S. Cornertpay, A. Dogan, G. Gaudino, S. Jube, S. Kanodia, C. R. Partridge, H. Pass, Z. Rivera, I. Steele, M. Tuncer, S. Way, H. Yang, and A. Miller. 2011. Erionite exposure in North Dakota and Turkish villages with mesothelioma Proceedings of the National Academy of Sciences 108:13618–23. doi:10.1073/pnas.1105887108
   PubMed Web of Science ®Google Scholar
• Carlin, D. J., T. C. Larson, J. C. Pfau, S. H. Gavett, A. Shukla, A. Miller, and R. Hines. 2015. Current research and opportunities to address environmental asbestos exposures. Environmental Health Perspectives 123:A194–97. doi:10.1289/ehp.1409662
   PubMed Web of Science ®Google Scholar
• Case, B. W., J. L. Abraham, G. Meeker, F. D. Pooley, and K. E. Pinkerton. 2011. Applying definitions of “asbestos” to environmental and “low-dose” exposure levels and health effects, particularly malignant mesothelioma. Journal of Toxicology and Environmental Health, Part B 14:3–39. doi:10.1080/10937404.2011.556045
   PubMed Web of Science ®Google Scholar
• Cheng, Y. Y., M. B. Kirschner, N. C. Cheng, S. Gattani, S. Klebe, J. J. Edelman, M. P. Vallely, B. C. McCaughan, H. C. Jin, N. Van Zandwijk, and G. Reid. 2013. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. Journal of Thoracic Oncology 8:1317–28. doi:10.1097/JTO.0b013e3182a0840a
   PubMed Web of Science ®Google Scholar
• Chirieac, L. R., J. A. Barletta, B. Y. Yeap, W. G. Richards, T. Tilleman, R. Bueno, E. H. Baldini, J. Godleski, and D. J. Sugarbaker. 2013. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. Journal of Clinical Oncology 31:4544–49. doi:10.1200/JCO.2013.49.9616
   PubMed Web of Science ®Google Scholar
• Christensen, B. C., E. A. Houseman, J. J. Godleski, C. J. Marsit, J. L. Longacker, C. R. Roelofs, M. R. Karagas, M. R. Wrensch, R. F. Yeh, H. H. Nelson, J. L. Wiemels, S. Zheng, J. K. Wiencke, R. Bueno, D. J. Sugarbaker, and K. T. Kelsey. 2009. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Research 69:227–34. doi:10.1158/0008-5472.CAN-08-2586
   PubMed Web of Science ®Google Scholar
• Christensen, B. C., E. A. Houseman, G. M. Poage, J. J. Godleski, R. Bueno, D. J. Sugarbaker, J. K. Wiencke, H. H. Nelson, C. J. Marsit, and K. T. Kelsey. 2010. Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Research 70:5686–94. doi:10.1158/0008-5472.CAN-10-0190
   PubMed Web of Science ®Google Scholar
• Churg, A., T. Allen, A. C. Borczuk, P. T. Cagle, F. Galateau-Salle, H. Hwang, B. Murer, V. V. Murty, N. Ordonez, H. D. Tazelaar, and M. Wick. 2014. Well-differentiated papillary mesothelioma with invasive foci. American Journal of Surgical Pathology 38:990–98. doi:10.1097/PAS.0000000000000200
   PubMed Web of Science ®Google Scholar
• Cioce, M., F. Ganci, V. Canu, A. Sacconi, F. Mori, C. Canino, E. Korita, B. Casini, G. Alessandrini, A. Cambria, M. A. Carosi, R. Blandino, V. Panebianco, F. Facciolo, P. Visca, S. Volinia, P. Muti, S. Strano, C. M. Croce, H. I. Pass, and G. Blandino. 2014. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 33:5319–31. doi:10.1038/onc.2013.476
   PubMed Web of Science ®Google Scholar
• Clin, B., F. Morlais, G. Launoy, A. V. Guizard, B. Dubois, V. Bouvier, N. Desoubeaux, M. F. Marquignon, C. Raffaelli, C. Paris, F. Galateau-Salle, L. Guittet, and M. Letourneux. 2011. Cancer incidence within a cohort occupationally exposed to asbestos: A study of dose-response relationships. Occupational and Environmental Medicine 68:832–36. doi:10.1136/oem.2010.059790
   PubMed Web of Science ®Google Scholar
• Comba, P., A. Gianfagna, and L. Paoletti. 2003. Pleural mesothelioma cases in Biancavilla are related to a new fluoro-edenite fibrous amphibole. Archives of Environmental Health 58:229–32. doi:10.3200/AEOH.58.4.229-232
   PubMed Web of Science ®Google Scholar
• Comertpay, S., S. Pastorino, M. Tanji, R. Mezzapelle, O. Strianese, A. Napolitano, F. Baumann, T. Weigel, J. Friedberg, P. Sugarbaker, T. Krausz, E. Wang, A. Powers, G. Gaudino, S. Kanodia, H. I. Pass, B. L. Parsons, H. Yang, and M. Carbone. 2014. Evaluation of clonal origin of malignant mesothelioma. Journal of Translational Medicine 12:301. doi:10.1186/s12967-014-0301-3
   PubMed Web of Science ®Google Scholar
• Cooke, W. E. 1924. Fibrosis of the lungs due to the inhalation of asbestos dust. British Medical Journal 2:140–42, 147. doi:10.1136/bmj.2.3317.147
   PubMedGoogle Scholar
• Crovella, S., A. M. Bianco, J. Vuch, L. Zupin, R. R. Moura, E. Trevisan, M. Scneider, A. Brollo, E. M. Nicastro, A. Cosenzi, G. Zabucchi, and V. Borelli. 2016. Iron sugnature in asbestos-induced malignant pleural mesothelioma: A population-based study. Journal of Toxicology and Environmental Health, Part A 79:129–41. doi:10.1080/15287394.2015.1123452
   PubMed Web of Science ®Google Scholar
• Cyphert, J. M., D. J. Carlin, A. Nyska, M. C. Schladweiler, A. D. Ledbetter, J. H. Shannahan, U. P. Kodavanti, and S. H. Gavett. 2015. Comparative long-term toxicity of Libby amphibole and amosite asbestos in rats after single or multiple intratracheal exposures. Journal of Toxicology and Environmental Health, Part A 78:151–65. doi:10.1080/15287394.2014.947455
   PubMed Web of Science ®Google Scholar
• Cyphert, J. M., M. A. McGee, A. Nyska, M. C. Schladweiler, A. D. U. P. Kodavanti, and S. H. Gavett. 2016. long-term toxicity of naturally occurring asbestos in male Fischer 344 rats. Journal of Toxicology and Environmental Health, Part A 79:49–60. doi:10.1080/15287394.2015.1099123
   PubMed Web of Science ®Google Scholar
• Cyphert, J. M., A. Nyska, R. K. Mahoney, M. C. Schladweiler, U. P. Kodavanti, and S. H. Gavett. 2012. Sumas Mountain chrysotile induces greater lung fibrosis in Fischer 344 rats than Libby amphibole, El Dorado tremolite, and Ontario ferroactinolite. Toxicological Sciences 130:405–15. doi:10.1093/toxsci/kfs249
   PubMed Web of Science ®Google Scholar
• Davidson, B. 2015. Prognostic factors in malignant pleural mesothelioma. Human Pathology 46:789–804. doi:10.1016/j.humpath.2015.02.006
   PubMed Web of Science ®Google Scholar
• Dawson, A., A. Gibbs, K. Browne, F. Pooley, and M. Griffiths. 1992. Familial mesothelioma. Details of 17 cases with histopathologic findings and mineral analysis. Cancer 70:1183–87. doi:10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• de Assis, L. V., J. Locatelli, and M. C. Isoldi. 2014. The role of key genes and pathways involved in the tumorigenesis of malignant mesothelioma. Biochimica et Biophysica Acta 1845:232–47.
   PubMed Web of Science ®Google Scholar
• de Reynies, A., M. C. Jaurand, A. Renier, G. Couchy, I. Hysi, N. Elarouci, F. Galateau-Salle, M. C. Copin, P. Hofman, A. Cazes, P. Andujar, S. Imbeaud, F. Petel, J. C. Pairon, F. Le Pimpec-Barthes, J. Zucman-Rossi, and D. Jean. 2014. Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clinical Cancer Research 20:1323–34. doi:10.1158/1078-0432.CCR-13-2429
   PubMed Web of Science ®Google Scholar
• De Rienzo, A., W. G. Richards, B. Y. Yeap, M. H. Coleman, P. E. Sugarbaker, L. R. Chirieac, Y. E. Wang, J. Quackenbush, R. V. Jensen, and R. Bueno. 2013. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clinical Cancer Research 19:2493–502. doi:10.1158/1078-0432.CCR-12-2117
   PubMed Web of Science ®Google Scholar
• Delgermaa, V., K. Takahashi, E. K. Park, G. V. Le, T. Hara, and T. Sorahan. 2011. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bulletin of the World Health Organization 89:716–24. doi:10.2471/BLT.00.000000
   PubMed Web of Science ®Google Scholar
• Doll, R. 1955. Mortality from lung cancer in asbestos workers. British Journal of Industrial Medicine 12:81–86.
   PubMedGoogle Scholar
• Donaldson, K., and C. A. Poland. 2012. Inhaled nanoparticles and lung cancer - what we can learn from conventional particle toxicology. Swiss Medical Weekly 142:w13547.
   PubMedGoogle Scholar
• Dunning, K. K., S. Adjei, L. Levin, A. M. Rohs, T. Hilbert, E. Borton, V. Kapil, C. Rice, G. K. Lemasters, and J. E. Lockey. 2012. Mesothelioma associated with commercial use of vermiculite containing Libby amphibole. Journal of Occupational and Environmental Medicine 54:1359–63. doi:10.1097/JOM.0b013e318250b5f5
   PubMed Web of Science ®Google Scholar
• Fang, R., N. Le, and P. Band. 2011. Identification of occupational cancer risks in British Columbia, Canada: A population-based case-control study of 1,155 cases of colon cancer. International Journal of Environmental Research and Public Health 8:3821–43. doi:10.3390/ijerph8103821
   PubMed Web of Science ®Google Scholar
• Farioli, A., F. S. Violante, S. Mattioli, S. Curti, and D. Kriebel. 2013. Risk of mesothelioma following external beam radiotherapy for prostate cancer: A cohort analysis of SEER database. Cancer Causes and Control 24:1535–45. doi:10.1007/s10552-013-0230-0
   PubMed Web of Science ®Google Scholar
• Farzin, M., C. W. Toon, A. Clarkson, L. Sioson, N. Watson, J. Andrici, and A. J. Gill. 2015. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 47:302–7. doi:10.1097/PAT.0000000000000250
   PubMed Web of Science ®Google Scholar
• Fatkhutdinova, L. M., T. O. Khaliullin, and A. A. Shvedova. 2015. Carbon nanotubes exposure risk assessment: From toxicology to epidemiologic studies (Overview of the current problem). Nanotechnologies in Russia 10:501–9. doi:10.1134/S1995078015030064
   PubMedGoogle Scholar
• Favoni, R. E., A. Daga, P. Malatesta, and T. Florio. 2012. Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. British Journal of Pharmacology 166:532–53. doi:10.1111/j.1476-5381.2012.01873.x
   PubMed Web of Science ®Google Scholar
• Felley-Bosco, E., and R. Stahel. 2014. Hippo/YAP pathway for targeted therapy. Translational Lung Cancer Research 3:75–83.
   PubMedGoogle Scholar
• Ferrante, D., D. Mirabelli, S. Tunesi, B. Terracini, and C. Magnani. 2016. Pleural mesothelioma and occupational and non-occupational asbestos exposure: A case-control study with quantitative risk assessment. Occupational and Environmental Medicine. 73:147–153.
   PubMed Web of Science ®Google Scholar
• Fleury-Feith, J., C. Lecomte, A. Renier, M. Matrat, L. Kheuang, V. Abramowski, F. Levy, A. Janin, M. Giovannini, and M. C. Jaurand. 2003. Hemizygosity of Nƒ2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 22:3799–805. doi:10.1038/sj.onc.1206593
   PubMed Web of Science ®Google Scholar
• Forbes, S. A., D. Beare, P. Gunasekaran, K. Leung, N. Bindal, H. Boutselakis, M. Ding, S. Bamford, C. Cole, S. Ward, C. Y. Kok, M. Jia, T. De, J. W. Teague, M. R. Stratton, U. McDermott, and P. J. Campbell. 2015. COSMIC: Exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Research 43:D805–11. doi:10.1093/nar/gku1075
   PubMed Web of Science ®Google Scholar
• Fortunato, L., and L. Rushton. 2015. Stomach cancer and occupational exposure to asbestos: A meta-analysis of occupational cohort studies. British Journal of Cancer 112:1805–15. doi:10.1038/bjc.2014.599
   PubMed Web of Science ®Google Scholar
• Fox, S. A., A. K. Richards, I. Kusumah, V. Perumal, E. M. Bolitho, S. E. Mutsaers, and A. M. Dharmarajan. 2013. Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells. Biochemical and Biophysical Research Communications 440:82–87. doi:10.1016/j.bbrc.2013.09.025
   PubMed Web of Science ®Google Scholar
• Frank, A. L., and T. K. Joshi. 2014. The global spread of asbestos. Annals of Global Health 80:257–62. doi:10.1016/j.aogh.2014.09.016
   PubMed Web of Science ®Google Scholar
• Frischknecht, L., M. Meerang, A. Soltermann, R. Stahel, H. Moch, B. Seifert, W. Weder, and I. Opitz. 2015. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. Journal of Thoracic and Cardiovascular Surgery 149:1539–46.e1531. doi:10.1016/j.jtcvs.2015.01.065
   PubMed Web of Science ®Google Scholar
• Frost, G. 2013. The latency period of mesothelioma among a cohort of British asbestos workers (1978–2005). British Journal of Cancer 109:1965–73. doi:10.1038/bjc.2013.514
   PubMed Web of Science ®Google Scholar
• Galateau-Salle, F., J. M. Vignaud, L. Burke, A. Gibbs, E. Brambilla, R. Attanoos, M. Goldberg, and G. Launoy. 2004. Well-differentiated papillary mesothelioma of the pleura: A series of 24 cases. American Journal of Surgical Pathology 28:534–40. doi:10.1097/00000478-200404000-00013
   PubMed Web of Science ®Google Scholar
• Genaidy, A., T. Tolaymat, R. Sequeira, M. Rinder, and D. Dionysiou. 2009. Health effects of exposure to carbon nanofibers: Systematic review, critical appraisal, meta analysis and research to practice perspectives. Science of the Total Environment 407:3686–701. doi:10.1016/j.scitotenv.2008.12.025
   PubMed Web of Science ®Google Scholar
• Ghani, F. I., H. Yamazaki, S. Iwata, T. Okamoto, K. Aoe, K. Okabe, Y. Mimura, N. Fujimoto, T. Kishimoto, T. Yamada, C. W. Xu, and C. Morimoto. 2011. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochemical and Biophysical Research Communications 404:735–42. doi:10.1016/j.bbrc.2010.12.054
   PubMed Web of Science ®Google Scholar
• Gordon, G. J., L. Dong, B. Y. Yeap, W. G. Richards, J. N. Glickman, H. Edenfield, M. Mani, R. Colquitt, G. Maulik, B. Van Oss, D. J. Sugarbaker, and R. Bueno. 2009. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. Journal of the National Cancer Institute 101:678–86. doi:10.1093/jnci/djp061
   PubMed Web of Science ®Google Scholar
• Gordon, G. J., R. V. Jensen, L. L. Hsiao, S. R. Gullans, J. E. Blumenstock, W. G. Richards, M. T. Jaklitsch, D. J. Sugarbaker, and R. Bueno. 2003. Using gene expression ratios to predict outcome among patients with mesothelioma. Journal of the National Cancer Institute 95:598–605. doi:10.1093/jnci/95.8.598
   PubMedGoogle Scholar
• Gordon, G. J., G. N. Rockwell, P. A. Godfrey, R. V. Jensen, J. N. Glickman, B. Y. Yeap, W. G. Richards, D. J. Sugarbaker, and R. Bueno. 2005. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clinical Cancer Research 11:4406–14. doi:10.1158/1078-0432.CCR-04-2181
   PubMed Web of Science ®Google Scholar
• Goswami, E., V. Craven, D. L. Dahlstrom, D. Alexander, and F. Mowat. 2013. Domestic asbestos exposure: A review of epidemiologic and exposure data. International Journal of Environmental Research and Public Health 10:5629–70. doi:10.3390/ijerph10115629
   PubMed Web of Science ®Google Scholar
• Goto, Y., K. Shinjo, Y. Kondo, L. Shen, M. Toyota, H. Suzuki, W. Gao, B. An, M. Fujii, H. Murakami, H. Osada, T. Taniguchi, N. Usami, M. Kondo, Y. Hasegawa, K. Shimokata, K. Matsuo, T. Hida, N. Fujimoto, T. Kishimoto, J. P. Issa, and Y. Sekido. 2009. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Research 69:9073–82. doi:10.1158/0008-5472.CAN-09-1595
   PubMed Web of Science ®Google Scholar
• Greim, H., M. J. Utell, L. D. Maxim, and R. Niebo. 2014. Perspectives on refractory ceramic fiber (RCF) carcinogenicity: Comparisons with other fibers. Inhalation Toxicology 26:789–810. doi:10.3109/08958378.2014.953276
   PubMed Web of Science ®Google Scholar
• Grosse, Y., D. Loomis, K. Z. Guyton, B. Lauby-Secretan, F. El Ghissassi, V. Bouvard, L. Benbrahim-Tallaa, N. Guha, C. Scoccianti, H. Mattock, and K. Straif. 2014. Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes. Lancet Oncology 15:1427–28. doi:10.1016/S1470-2045(14)71109-X
   PubMed Web of Science ®Google Scholar
• Guo, G., J. Chmielecki, C. Goparaju, A. Heguy, I. Dolgalev, M. Carbone, S. Seepo, M. Meyerson, and H. I. Pass. 2015. Whole exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma. Cancer Research 75:264–69. doi:10.1158/0008-5472.CAN-14-1008
   PubMed Web of Science ®Google Scholar
• Hillegass, J. M., J. M. Miller, M. B. MacPherson, C. M. Westbom, M. Sayan, J. K. Thompson, S. L. Macura, T. N. Perkins, S. L. Beuschel, V. Alexeeva, H. I. Pass, C. Steele, B. T. Mossman, and A. Shukla. 2013. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Particle and Fibre Toxicology 10:39. doi:10.1186/1743-8977-10-39
   PubMed Web of Science ®Google Scholar
• Hillerdal, G. 1999. Mesothelioma: Cases associated with non-occupational and low dose exposures. Occupational and Environmental Medicine 56:505–13. doi:10.1136/oem.56.8.505
   PubMed Web of Science ®Google Scholar
• Hoang, C. D., J. D’Cunha, M. G. Kratzke, C. E. Casmey, S. P. Frizelle, M. A. Maddaus, and R. A. Kratzke. 2004. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 125:1843–52. doi:10.1378/chest.125.5.1843
   PubMed Web of Science ®Google Scholar
• Holloway, A. J., D. S. Diyagama, K. Opeskin, J. Creaney, B. W. Robinson, R. A. Lake, and D. D. Bowtell. 2006. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clinical Cancer Research 12:5129–35. doi:10.1158/1078-0432.CCR-06-1027
   PubMed Web of Science ®Google Scholar
• Husain, A. N., T. Colby, N. Ordonez, T. Krausz, R. Attanoos, M. B. Beasley, A. C. Borczuk, K. Butnor, P. T. Cagle, L. R. Chirieac, A. Churg, S. Dacic, A. Fraire, F. Galateau-Salle, A. Gibbs, A. Gown, S. Hammar, L. Litzky, A. M. Marchevsky, A. Nicholson, V. Roggli, W. D. Travis, and M. Wick. 2013. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 Update of the consensus statement from the International Mesothelioma Interest Group. Archives of Pathology & Laboratory Medicine 137:647–67. doi:10.5858/arpa.2012-0214-OA
   PubMed Web of Science ®Google Scholar
• Hwang, H. C., B. S. Sheffield, S. Rodriguez, K. Thompson, C. H. Tse, A. M. Gown, and A. Churg. 2015. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. American Journal of Surgical Pathology 40:120–26. doi:10.1097/PAS.0000000000000529
   Web of Science ®Google Scholar
• IARC. 2002. Man-made vitreous fibres. IARC monographs on the valuation of carcinogenic risks to humans, vo. 81. Lyon, France: IARC Press.
   Google Scholar
• IARC. 2012. Arsenic, metals, fibres, and dusts. A review of human carcinogens IARC monographs on the evaluation of carcinogenic risks to humans, vol. 100C. Lyon, France: IARC Press.
   Google Scholar
• Jasani, B., and A. Gibbs. 2012. Mesothelioma not associated with asbestos exposure. Archives of Pathology & Laboratory Medicine 136:262–67. doi:10.5858/arpa.2011-0039-RA
   PubMed Web of Science ®Google Scholar
• Jaurand, M. C. 2015. Health effects of carbon nanotubes and some comparisons with natural mineral nanotubes. In Natural mineral nanotubes. Properties and applications, ed. P. Pooria Pasbakhsh, and G. Jock Churchman, 461–480. Oakville, ON, Canada: Apple Academic Press.
   Google Scholar
• Jaurand, M. C. In press. Safety of tubular clay minerals: An overview. In Nanosized tubular clay minerals, ed. P. Yuan, A. Thill, and F. Bergaya, 485–508. Elsevier.
   Google Scholar
• Jaurand, M. C., and D. Jean. 2016. Biomolecular pathways and malignant pleural mesothelioma. In Malignant pleural mesothelioma: Present status and future directions, ed. T. C. Mineo, 173–196. Sharjah, UAE: Bentham Science Publishers.
   Google Scholar
• Jean, D., J. Daubriac, F. Le Pimpec-Barthes, F. Galateau-Salle, and M. C. Jaurand. 2012. Molecular changes in mesothelioma with an impact on prognosis and treatment. Archives of Pathology & Laboratory Medicine 136:277–93. doi:10.5858/arpa.2011-0215-RA
   PubMed Web of Science ®Google Scholar
• Jean, D., E. Thomas, A. Renier, A. De Reynies, C. Lecomte, P. Andujar, J. Fleury-Feith, M. Giovannini, J. Zucman-Rossi, M. H. Stern, and M. C. Jaurand. 2011. Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. American Journal of Pathology 176:881–94. doi:10.1016/j.ajpath.2010.10.039
   Web of Science ®Google Scholar
• Kameda, T., K. Takahashi, R. Kim, Y. Jiang, M. Movahed, E. K. Park, and J. Rantanen. 2014. Asbestos: Use, bans and disease burden in Europe. Bulletin of the World Health Organization 92:790–97. doi:10.2471/BLT.13.132118
   PubMed Web of Science ®Google Scholar
• Kanarek, M. S. 2011. Mesothelioma from chrysotile asbestos: Update. Annals of Epidemiology 21:688–97. doi:10.1016/j.annepidem.2011.05.010
   PubMed Web of Science ®Google Scholar
• Kang, H. C., H. K. Kim, S. Lee, P. Mendez, J. W. Kim, G. Woodard, J. H. Yoon, K. Y. Jen, L. T. Fang, K. Jones, D. M. Jablons, and I. J. Kim. 2016. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 7:8321–31.
   PubMed Web of Science ®Google Scholar
• Kao, S. C., M. Fulham, K. Wong, W. Cooper, H. Brahmbhatt, J. MacDiarmid, S. Pattison, J. O. Sagong, Y. Huynh, F. Leslie, N. Pavlakis, S. Clarke, M. Boyer, G. Reid, and N. vanZandwijk. 2015. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine 191:1467–69. doi:10.1164/rccm.201503-0461LE
   PubMed Web of Science ®Google Scholar
• Kayat, J., V. Gajbhiye, R. K. Tekade, and N. K. Jain. 2011. Pulmonary toxicity of carbon nanotubes: A systematic report. Nanomedicine 7:40–49.
   PubMed Web of Science ®Google Scholar
• Kirschner, M. B., Y. Y. Cheng, N. J. Armstrong, R. C. Lin, S. C. Kao, A. Linton, S. Klebe, B. C. McCaughan, N. Van Zandwijk, and G. Reid. 2015. MiR-score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology 9:715–26. doi:10.1016/j.molonc.2014.11.007
   PubMed Web of Science ®Google Scholar
• Klorin, G., E. Rozenblum, O. Glebov, R. L. Walker, Y. Park, P. S. Meltzer, I. R. Kirsch, F. J. Kaye, and A. V. Roschke. 2013. Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines. Cancer Genetics 206:191–205. doi:10.1016/j.cancergen.2013.04.006
   PubMed Web of Science ®Google Scholar
• Kodavanti, U. P., D. Andrews, M. C. Schladweiler, S. H. Gavett, D. E. Dodd, and J. M. Cyphert. 2014. Early and delayed effects of naturally occurring asbestos on serum biomarkers of inflammation and metabolism. Journal of Toxicology and Environmental Health, Part A 77:1024–39. doi:10.1080/15287394.2014.899171
   PubMed Web of Science ®Google Scholar
• Kurumatani, N., and S. Kumagai. 2008. Mapping the risk of mesothelioma due to neighborhood asbestos exposure. American Journal of Respiratory and Critical Care Medicine 178:624–29. doi:10.1164/rccm.200801-063OC
   PubMed Web of Science ®Google Scholar
• Lacourt, A., C. Gramond, S. Audignon, S. Ducamp, J. Fevotte, A. G. Soit Ilg, M. Goldberg, E. Imbernon, and P. Brochard. 2013. Pleural mesothelioma and occupational coexposure to asbestos, mineral wool, and silica. American Journal of Respiratory and Critical Care Medicine 187:977–82. doi:10.1164/rccm.201210-1911OC
   PubMed Web of Science ®Google Scholar
• Lacourt, A., M. Rinaldo, C. Gramond, S. Ducamp, A. Gilg Soit Ilg, M. Goldberg, J. C. Pairon, and P. Brochard. 2014. Co-exposure to refractory ceramic fibres and asbestos and risk of pleural mesothelioma. European Respiratory Journal 44:725–33. doi:10.1183/09031936.00079814
   PubMed Web of Science ®Google Scholar
• Lambert, C. S., B. H. Alexander, G. Ramachandran, R. F. MacLehose, H. H. Nelson, A. D. Ryan, and J. H. Mandel. 2016. A case-control study of mesothelioma in Minnseota iron ore (taconite) miners. Occupational and Environmental Medicine 743:103–9.
   Google Scholar
• Langevin, S. M., M. H. O’Sullivan, J. L. Valerio, M. Pawlita, K. M. Applebaum, M. Eliot, M. D. McClean, and K. T. Kelsey. 2013. Occupational asbestos exposure is associated with pharyngeal squamous cell carcinoma in men from the greater Boston area. Occupational and Environmental Medicine 70:858–63. doi:10.1136/oemed-2013-101528
   PubMed Web of Science ®Google Scholar
• Lecouvet, B. 2015. Some further industrial, environmental and biomedical applications of halloysite nanotubes. In Natural mineral nanotubes. Properties and applications, ed. P. P. Pasbakhsh, and P. G. J. Churchman, 383–406. Oakville, ON, Canada: Apple Academic Press.
   Google Scholar
• Li, B., S. P. Tang, and K. Z. Wang. 2015. Esophagus cancer and occupational exposure to asbestos: Results from a meta-analysis of epidemiology studies. Diseases of the Esophagus. doi:10.1111/dote.12341.
   Google Scholar
• Lim, C. B., C. M. Prele, H. M. Cheah, Y. Y. Cheng, S. Klebe, G. Reid, D. N. Watkins, S. Baltic, P. J. Thompson, and S. E. Mutsaers. 2013. Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. PLoS ONE 8:e66685. doi:10.1371/journal.pone.0066685
   Google Scholar
• Lippmann, M. 2014. Toxicological and epidemiological studies on effects of airborne fibers: Coherence and public [corrected] health implications. Critical Reviews in Toxicology 44:643–95. doi:10.3109/10408444.2014.928266
   PubMed Web of Science ®Google Scholar
• Lo Iacono, M., V. Monica, L. Righi, F. Grosso, R. Libener, S. Vatrano, P. Bironzo, S. Novello, L. Musmeci, M. Volante, M. Papotti, and G. V. Scagliotti. 2015. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study. Journal of Thoracic Oncology 10:492–99. doi:10.1097/JTO.0000000000000436
   PubMed Web of Science ®Google Scholar
• Lockey, J., G. Lemsters, C. Rice, K. Hansen, L. Levin, R. Shipley, H. Spitz, and J. Wiot. 1996. Refractory ceramic fiber exposure and pleural plaques. American Journal of Respiratory and Critical Care Medicine 154:1405–10. doi:10.1164/ajrccm.154.5.8912756
   PubMed Web of Science ®Google Scholar
• Lockey, J. E., G. K. LeMasters, L. Levin, C. Rice, J. Yiin, S. Reutman, and D. Papes. 2002. A longitudinal study of chest radiographic changes of workers in the refractory ceramic fiber industry. Chest 121:2044–51. doi:10.1378/chest.121.6.2044
   PubMed Web of Science ®Google Scholar
• Lopez-Rios, F., S. Chuai, R. Flores, S. Shimizu, T. Ohno, K. Wakahara, P. B. Illei, S. Hussain, L. Krug, M. F. Zakowski, V. Rusch, A. B. Olshen, and M. Ladanyi. 2006. Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Research 66:2970–79. doi:10.1158/0008-5472.CAN-05-3907
   PubMed Web of Science ®Google Scholar
• Maisanaba, S., S. Pichardo, M. Puerto, D. Gutierrez-Praena, A. M. Camean, and A. Jos. 2015. Toxicological evaluation of clay minerals and derived nanocomposites: A review. Environmental Research 138:233–54. doi:10.1016/j.envres.2014.12.024
   PubMed Web of Science ®Google Scholar
• Matsumoto, S., K. Nabeshima, M. Hamasaki, T. Shibuta, and T. Umemura. 2014. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. Medical Oncology 31:303. doi:10.1007/s12032-014-0303-2
   PubMed Web of Science ®Google Scholar
• Melaiu, O., E. Bracci, A. Cristaudo, A. Bonotti, R. Foddis, L. Mutti, F. Gemignani, and S. Landi. 2013. Comparative genomic hybridization studies on mesothelioma show a parallel fate of 1p21-1p22 and 9p21 bands and a chromosomally stable sub-group. American Journal of Medical and Biological Research 1:149–58. doi:10.12691/ajmbr-1-4-8
   Google Scholar
• Melaiu, O., A. Cristaudo, E. Melissari, M. Di Russo, A. Bonotti, R. Bruno, R. Foddis, F. Gemignani, S. Pellegrini, and S. Landi. 2012. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. Mutation Research/Reviews in Mutation Research 750:132–40. doi:10.1016/j.mrrev.2011.12.003
   PubMed Web of Science ®Google Scholar
• Melaiu, O., E. Melissari, L. Mutti, E. Bracci, C. De Santi, C. Iofrida, M. Di Russo, A. Cristaudo, A. Bonotti, M. Cipollini, S. I. Garritano, R. Foddis, M. Lucchi, S. Pellegrini, F. Gemignani, and S. Landi. 2015. Expression status of candidate genes in mesothelioma tissues and cell lines. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 771:6–12. doi:10.1016/j.mrfmmm.2014.11.002
   PubMed Web of Science ®Google Scholar
• Menvielle, G., A. Fayosse, L. Radoi, F. Guida, M. Sanchez, M. Carton, D. Cyr, A. Schmaus, S. Cenee, J. Fevotte, P. Delafosse, I. Stucker, and D. Luce. 2016. The joint effect of asbestos exposure, tobacco smoking and alcohol drinking on laryngeal cancer risk: Evidence from the French population-based case-control study, ICARE. Occupational and Environmental Medicine 73:28–33.
   PubMed Web of Science ®Google Scholar
• Mezzapelle, R., U. Miglio, O. Rena, A. Paganotti, S. Allegrini, J. Antona, F. Molinari, M. Frattini, G. Monga, O. Alabiso, and R. Boldorini. 2013. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. British Journal of Cancer 108:1743–49. doi:10.1038/bjc.2013.130
   PubMed Web of Science ®Google Scholar
• Miyanaga, A., M. Masuda, K. Tsuta, K. Kawasaki, Y. Nakamura, T. Sakuma, H. Asamura, A. Gemma, and T. Yamada. 2015. Hippo pathway gene mutations in malignant mesothelioma: Revealed by RNA and targeted exon sequencing Journal of Thoracic Oncology 10:844–51. doi:10.1097/JTO.0000000000000493
   PubMed Web of Science ®Google Scholar
• Mossman, B. T., M. Lippmann, T. W. Hesterberg, K. T. Kelsey, A. Barchowsky, and J. C. Bonner 2011. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. Journal of Toxicology and Environmental Health, Part B 14:76–121. doi:10.1080/10937404.2011.556047
   PubMed Web of Science ®Google Scholar
• Murakami, H., T. Mizuno, T. Taniguchi, M. Fujii, F. Ishiguro, T. Fukui, S. Akatsuka, Y. Horio, T. Hida, Y. Kondo, S. Toyokuni, H. Osada, and Y. Sekido. 2011. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Research 71:873–83. doi:10.1158/0008-5472.CAN-10-2164
   PubMed Web of Science ®Google Scholar
• Murali, R., T. Wiesner, and R. A. Scolyer. 2013. Tumours associated with BAP1 mutations. Pathology 45:116–26. doi:10.1097/PAT.0b013e32835d0efb
   PubMed Web of Science ®Google Scholar
• Musk, A. W., N. Olsen, H. Alfonso, A. Reid, R. Mina, P. Franklin, J. Sleith, N. Hammond, T. Threlfall, K. B. Shilkin, and N. H. de Klerk. 2011. Predicting survival in malignant mesothelioma. European Respiratory Journal 38:1420–24. doi:10.1183/09031936.00000811
   PubMed Web of Science ®Google Scholar
• Nasu, M., M. Emi, S. Pastorino, M. Tanji, A. Powers, H. Luk, F. Baumann, Y. A. Zhang, A. Gazdar, S. Kanodia, M. Tiirikainen, E. Flores, G. Gaudino, M. J. Becich, H. I. Pass, H. Yang, and M. Carbone. 2015. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. Journal of Thoracic Oncology 10:565–76. doi:10.1097/JTO.0000000000000471
   PubMed Web of Science ®Google Scholar
• NIOSH. 2011. Asbestos fibers and other elongate mineral particles: State of the science and roadmap for research. Revised April 2011. Current Intelligence Bulletin 62:1–153.
   Google Scholar
• Oberdorster, G., V. Castranova, B. Asgharian, and P. Sayre. 2015. Inhalation exposure to carbon nanotubes (CNT) and carbon nanofibers (CNF): Methodology and dosimetry. Journal of Toxicology and Environmental Health, Part B 18:121–212. doi:10.1080/10937404.2015.1051611
   PubMed Web of Science ®Google Scholar
• Offermans, N. S., R. Vermeulen, A. Burdorf, R. A. Goldbohm, T. Kauppinen, H. Kromhout, and P. A. Van Den Brandt. 2014a. Occupational asbestos exposure and risk of pleural mesothelioma, lung cancer, and laryngeal cancer in the prospective Netherlands cohort study. Journal of Occupational and Environmental Medicine 56:6–19. doi:10.1097/JOM.0000000000000060
   PubMed Web of Science ®Google Scholar
• Offermans, N. S., R. Vermeulen, A. Burdorf, R. A. Goldbohm, A. P. Keszei, S. Peters, T. Kauppinen, H. Kromhout, and P. A. Van Den Brandt. 2014b. Occupational asbestos exposure and risk of esophageal, gastric and colorectal cancer in the prospective Netherlands cohort study. International Journal of Cancer 135:1970–77. doi:10.1002/ijc.28817
   PubMed Web of Science ®Google Scholar
• Ortega-Guerrero, M. A., G. Carrasco-Nunez, H. Barragan-Campos, and M. R. Ortega. 2015. High incidence of lung cancer and malignant mesothelioma linked to erionite fibre exposure in a rural community in Central Mexico. Occupational and Environmental Medicine 72:216–18. doi:10.1136/oemed-2013-101957
   PubMed Web of Science ®Google Scholar
• Pairon, J. C., P. Andujar, M. Rinaldo, J. Ameille, P. Brochard, S. Chamming’s, B. Clin, G. Ferretti, A. Gislard, F. Laurent, A. Luc, P. Wild, and C. Paris. 2014. Asbestos exposure, pleural plaques, and the risk of death from lung cancer. American Journal of Respiratory and Critical Care Medicine 190:1413–20. doi:10.1164/rccm.201406-1074OC
   PubMed Web of Science ®Google Scholar
• Pairon, J. C., F. Laurent, M. Rinaldo, B. Clin, P. Andujar, J. Ameille, P. Brochard, S. Chammings, G. Ferretti, F. Galateau-Salle, A. Gislard, M. Letourneux, A. Luc, E. Schorle, and C. Paris. 2013. Pleural plaques and the risk of pleural mesothelioma. Journal of the National Cancer Institute 105:293–301. doi:10.1093/jnci/djs513
   PubMedGoogle Scholar
• Panagopoulos, I., J. Thorsen, L. Gorunova, F. Micci, L. Haugom, B. Davidson, and S. Heim. 2013. RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12). Genes Chromosomes and Cancer 52:733–40. doi:10.1002/gcc.22068
   PubMed Web of Science ®Google Scholar
• Panou, V., M. Vyberg, U. M. Weinreich, C. Meristoudis, U. G. Falkmer, and O. D. Roe. 2015. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treatment Reviews 41:486–95. doi:10.1016/j.ctrv.2015.05.001
   PubMed Web of Science ®Google Scholar
• Pasdar, E. A., M. Smits, M. Stapelberg, M. Bajzikova, M. Stantic, J. Goodwin, B. Yan, J. Stursa, J. Kovarova, K. Sachaphibulkij, A. Bezawork-Geleta, M. Sobol, A. Filimonenko, M. Tomasetti, R. Zobalova, P. Hozak, L. F. Dong, and J. Neuzil. 2015. Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents. PLoS ONE 10:e0119549. doi:10.1371/journal.pone.0119549
   Google Scholar
• Pass, H. I., C. Goparaju, S. Ivanov, J. Donington, M. Carbone, M. Hoshen, D. Cohen, A. Chajut, S. Rosenwald, H. Dan, S. Benjamin, and R. Aharonov. 2010. Hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Research 70:1916–24. doi:10.1158/0008-5472.CAN-09-3993
   PubMed Web of Science ®Google Scholar
• Pass, H. I., Z. Liu, A. Wali, R. Bueno, S. Land, D. Lott, F. Siddiq, F. Lonardo, M. Carbone, and S. Draghici. 2004. Gene expression profiles predict survival and progression of pleural mesothelioma. Clinical Cancer Research 10:849–59. doi:10.1158/1078-0432.CCR-0607-3
   PubMed Web of Science ®Google Scholar
• Peters, G. J., A. Avan, M. G. Ruiz, V. Orsini, A. Avan, E. Giovannetti, and E. F. Smit. 2014. Predictive role of repair enzymes in the efficacy of cisplatin combinations in pancreatic and lung cancer. Anticancer Research 34:435–42.
   PubMed Web of Science ®Google Scholar
• Petrilli, A. M., and C. Fernandez-Valle. 2015. Role of merlin/NF2 inactivation in tumor biology. Oncogene 35:537–48. doi:10.1038/onc.2015.125
   PubMed Web of Science ®Google Scholar
• Pintos, J., M. E. Parent, B. W. Case, M. C. Rousseau, and J. Siemiatycki. 2009. Risk of mesothelioma and occupational exposure to asbestos and man-made vitreous fibers: Evidence from two case-control studies in Montreal, Canada. Journal of Occupational and Environmental Medicine 51:1177–84. doi:10.1097/JOM.0b013e3181b68cef
   PubMed Web of Science ®Google Scholar
• Pohl, S., R. Scott, F. Arfuso, V. Perumal, and A. Dharmarajan. 2015. Secreted frizzled-related protein 4 and its implications in cancer and apoptosis. Tumor Biology 36:143–52. doi:10.1007/s13277-014-2956-z
   PubMed Web of Science ®Google Scholar
• Pukkala, E., J. I. Martinsen, E. Weiderpass, K. Kjaerheim, E. Lynge, L. Tryggvadottir, P. Sparen, and P. A. Demers. 2014. Cancer incidence among firefighters: 45 Years of follow-up in five Nordic countries. Occupational and Environmental Medicine 71:398–404. doi:10.1136/oemed-2013-101803
   PubMed Web of Science ®Google Scholar
• Rake, C., C. Gilham, J. Hatch, A. Darnton, J. Hodgson, and J. Peto. 2009. Occupational, domestic and environmental mesothelioma risks in the British population: A case-control study. British Journal of Cancer 100:1175–83. doi:10.1038/sj.bjc.6604879
   PubMed Web of Science ®Google Scholar
• Rapisarda, V., C. Ledda, V. Ricceri, F. Arena, A. Musumeci, A. Marconi, L. Fago, M. Bracci, L. Santarelli, and M. Ferrante. 2015. Detection of pleural plaques in workers exposed to inhalation of natural fluoro-edenite fibres. Oncology Letters 9:2046–52.
   PubMed Web of Science ®Google Scholar
• Reid, A., P. Franklin, N. Olsen, J. Sleith, L. Samuel, P. Aboagye-Sarfo, N. De Klerk, and A. W. Musk. 2013. All-cause mortality and cancer incidence among adults exposed to blue asbestos during childhood. American Journal of Industrial Medicine 56:133–45. doi:10.1002/ajim.v56.2
   PubMed Web of Science ®Google Scholar
• Reid, G. 2015. MicroRNAs in mesothelioma: From tumour suppressors and biomarkers to therapeutic targets. Journal of Thoracic Disease 7:1031–40.
   PubMed Web of Science ®Google Scholar
• Robinson, B. W., A. W. Musk, and R. A. Lake. 2005. Malignant mesothelioma. Lancet 366:397–408. doi:10.1016/S0140-6736(05)67025-0
   PubMed Web of Science ®Google Scholar
• Rodelsperger, K., K. H. Jockel, H. Pohlabeln, W. Romer, and H. J. Woitowitz. 2001. Asbestos and man-made vitreous fibers as risk factors for diffuse malignant mesothelioma: Results from a German hospital-based case-control study. American Journal of Industrial Medicine 39:262–75. doi:10.1002/1097-0274(200103)39:3<262::AID-AJIM1014>3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Rolland, P., C. Gramond, A. Lacourt, P. Astoul, S. Chamming’s, S. Ducamp, C. Frenay, F. Galateau-Salle, A. G. Ilg, E. Imbernon, N. Le Stang, J. C. Pairon, M. Goldberg, and P. Brochard. 2010. Occupations and industries in France at high risk for pleural mesothelioma: A population-based case-control study (1998–2002). American Journal of Industrial Medicine 53:1207–19. doi:10.1002/ajim.20895
   PubMed Web of Science ®Google Scholar
• Rusch, A., G. Ziltener, K. Nackaerts, W. Weder, R. A. Stahel, and E. Felley-Bosco. 2015. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer 87:77–79. doi:10.1016/j.lungcan.2014.10.017
   PubMed Web of Science ®Google Scholar
• Scherpereel, A., P. Astoul, P. Baas, T. Berghmans, H. Clayson, P. De Vuyst, H. Dienemann, F. Galateau-Salle, C. Hennequin, G. Hillerdal, C. Le Pechoux, L. Mutti, J. C. Pairon, R. Stahel, P. Van Houtte, J. Van Meerbeeck, D. Waller, and W. Weder. 2010. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal 35:479–95. doi:10.1183/09031936.00063109
   PubMed Web of Science ®Google Scholar
• Schildgen, V., O. Pabst, R. L. Tillmann, J. Lusebrink, O. Schildgen, C. Ludwig, M. Brockmann, and E. Stoelben. 2015. Low frequency of EGFR mutations in pleural mesothelioma patients, Cologne, Germany. Applied Immunohistochemistry & Molecular Morphology 23:118–25. doi:10.1097/PDM.0b013e3182a3645e
   Web of Science ®Google Scholar
• Schreiber, N., M. Strobele, R. Hochscheid, E. Kotte, P. Weber, H. Bockhorn, and B. Muller. 2016. Modifications of carbon black nanoparticle surfaces modulate type II pneumocyte homeostasis. Journal of Toxicology and Environmental Health. Part A 79:153–64.
   PubMed Web of Science ®Google Scholar
• Sebastien, P., A. Fondimare, J. Bignon, G. Monchaux, J. Desbordes, and G. Bonnaud. 1975. Topographic distribution of asbestos fibres in human lung in relation to occupational and non-occupational exposure. Inhaled Particles 4:435–46.
   PubMedGoogle Scholar
• Sekido, Y. 2010. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Science 101:1–6. doi:10.1111/cas.2009.101.issue-1
   PubMed Web of Science ®Google Scholar
• Sekido, Y. 2013. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34:1413–19. doi:10.1093/carcin/bgt166
   PubMed Web of Science ®Google Scholar
• Selikoff, I. J., J. Churg, and E. C. Hammond. 1964. Asbestos exposure and neoplasia. Journal of the American Medical Association 188:22–26. doi:10.1001/jama.1964.03060270028006
   PubMed Web of Science ®Google Scholar
• Shukuya, T., M. Serizawa, M. Watanabe, H. Akamatsu, M. Abe, H. Imai, T. Tokito, A. Ono, T. Taira, H. Kenmotsu, T. Naito, H. Murakami, T. Takahashi, M. Endo, Y. Ohde, T. Nakajima, N. Yamamoto, and Y. Koh. 2014. Identification of actionable mutations in malignant pleural mesothelioma. Lung Cancer 86:35–40. doi:10.1016/j.lungcan.2014.08.004
   PubMed Web of Science ®Google Scholar
• Shvedova, A. A., E. R. Kisin, D. Porter, P. Schulte, V. E. Kagan, B. Fadeel, and V. Castranova. 2009. Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus? Pharmacology & Therapeutics 121:192–204. doi:10.1016/j.pharmthera.2008.10.009
   PubMed Web of Science ®Google Scholar
• Shvedova, A. A., N. Yanamala, E. R. Kisin, T. O. Khailullin, M. E. Birch, and L. M. Fatkhutdinova. 2016. Integrated analysis of dysregulated ncRNA and mRNA expression profiles in humans exposed to carbon nanotubes. PLoS ONE 11:e0150628. doi:10.1371/journal.pone.0150628
   PubMed Web of Science ®Google Scholar
• Simson, F. W. 1928. Pulmonary asbestosis in South Africa. British Medical Journal 1:885–87. doi:10.1136/bmj.1.3516.885
   Google Scholar
• Spirtas, R., E. F. Heineman, L. Bernstein, G. W. Beebe, R. J. Keehn, A. Stark, B. L. Harlow, and J. Benichou. 1994. Malignant mesothelioma: Attributable risk of asbestos exposure. Occupational and Environmental Medicine 51:804–11. doi:10.1136/oem.51.12.804
   PubMed Web of Science ®Google Scholar
• Stayner, L., L. S. Welch, and R. Lemen. 2013. The worldwide pandemic of asbestos-related diseases. Annual Review of Public Health 34:205–16. doi:10.1146/annurev-publhealth-031811-124704
   PubMed Web of Science ®Google Scholar
• Suraokar, M. B., M. I. Nunez, L. Diao, C. W. Chow, D. Kim, C. Behrens, H. Lin, S. Lee, G. Raso, C. Moran, D. Rice, R. Mehran, J. J. Lee, H. I. Pass, J. Wang, A. A. Momin, B. P. James, A. Corvalan, K. Coombes, A. Tsao, and I. I. Wistuba 2014. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Annals of Oncology 25:1184–92. doi:10.1093/annonc/mdu127
   PubMed Web of Science ®Google Scholar
• Tallet, A., J. C. Nault, A. Renier, I. Hysi, F. Galateau-Salle, A. Cazes, M. C. Copin, P. Hofman, P. Andujar, F. Le Pimpec-Barthes, J. Zucman-Rossi, M. C. Jaurand, and D. Jean. 2014. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 33:3748–52. doi:10.1038/onc.2013.351
   PubMed Web of Science ®Google Scholar
• Tarres, J., C. Alberti, X. Martinez-Artes, R. Abos-Herrandiz, M. Rosell-Murphy, I. Garcia-Allas, I. Krier, G. Cantarell, M. Gallego, J. Canela-Soler, and R. Orriols. 2013. Pleural mesothelioma in relation to meteorological conditions and residential distance from an industrial source of asbestos. Occupational and Environmental Medicine 70:588–90. doi:10.1136/oemed-2012-101198
   PubMed Web of Science ®Google Scholar
• Testa, J. R., M. Cheung, J. Pei, J. E. Below, Y. Tan, E. Sementino, N. J. Cox, A. U. Dogan, H. I. Pass, S. Trusa, M. Hesdorffer, M. Nasu, A. Powers, Z. Rivera, S. Comertpay, M. Tanji, G. Gaudino, H. Yang, and M. Carbone. 2011. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics 43:1022–25. doi:10.1038/ng.912
   PubMed Web of Science ®Google Scholar
• Thies, S., M. Friess, L. Frischknecht, D. Korol, E. Felley-Bosco, R. Stahel, B. Vrugt, W. Weder, I. Opitz, and A. Soltermann. 2015. Expression of the stem cell factor nestin in malignant pleural mesothelioma is associated with poor prognosis. PLoS ONE 10:e0139312. doi:10.1371/journal.pone.0139312
   Google Scholar
• Thurneysen, C., I. Opitz, S. Kurtz, W. Weder, R. A. Stahel, and E. Felley-Bosco. 2009. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 64:140–47. doi:10.1016/j.lungcan.2008.08.014
   PubMed Web of Science ®Google Scholar
• Toumpanakis, D., and S. E. Theocharis. 2011. DNA repair systems in malignant mesothelioma. Cancer Letters 312:143–49. doi:10.1016/j.canlet.2011.08.021
   PubMed Web of Science ®Google Scholar
• Tran, C. L., R. Trantra, K. Donaldson, V. Stone, S. M. Hankin, B. Ross, R. J. Aitknen, and A. D. Jones. 2011. A hypothetical model for predicting the toxicity of high aspect ratio nanoparticles (HARN). Journal of Nanoparticle Research 13:6683–98. doi:10.1007/s11051-011-0575-9
   Web of Science ®Google Scholar
• Tran, P. A., L. Zhang, and T. J. Webster. 2009. Carbon nanofibers and carbon nanotubes in regenerative medicine. Advanced Drug Delivery Reviews 61:1097–114. doi:10.1016/j.addr.2009.07.010
   PubMed Web of Science ®Google Scholar
• Ueno, T., S. Toyooka, T. Fukazawa, T. Kubo, J. Soh, H. Asano, T. Muraoka, N. Tanaka, Y. Maki, K. Shien, M. Furukawa, M. Sakaguchi, H. Yamamoto, K. Tsukuda, and S. Miyoshi. 2014. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta Medica Okayama 68:23–26.
   PubMed Web of Science ®Google Scholar
• Upadhyayula, V. K., S. Deng, M. C. Mitchell, and G. B. Smith. 2009. Application of carbon nanotube technology for removal of contaminants in drinking water: A review. Science of the Total Environment 408:1–13. doi:10.1016/j.scitotenv.2009.09.027
   PubMed Web of Science ®Google Scholar
• Vahedi, V., and P. Pasbakhsh. 2015. Applications of natural mineral nanotubes in nanocomposites. In Natural mineral nanotubes. Properties and applications, ed. P. P. Pasbakhsh, and P. G. J. Churchman, 141–172. Oakville, ON, Canada: Apple Academic Press.
   Google Scholar
• van der Bij, S., H. Koffijberg, V. Lenters, L. Portengen, K. G. Moons, D. Heederik, and R. C. Vermeulen. 2013. Lung cancer risk at low cumulative asbestos exposure: Meta-regression of the exposure-response relationship. Cancer, Causes and Control 24:1–12. doi:10.1007/s10552-012-0107-7
   PubMed Web of Science ®Google Scholar
• Vandermeers, F., S. Neelature Sriramareddy, C. Costa, R. Hubaux, J. P. Cosse, and L. Willems. 2013. The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 81:311–18. doi:10.1016/j.lungcan.2013.05.014
   PubMed Web of Science ®Google Scholar
• Wagner, J. C., C. A. Sleggs, and P. Marchand. 1960. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. British Journal of Industrial Medicine 17:260–71.
   PubMedGoogle Scholar
• Wylie, A. G., and P. A. Candela. 2015. Methodologies for determining the sources, characteristics, distribution and abundance of asbestiform and nonasbestestiform amphibole and serpentine in ambient air and water. Journal of Toxicology and Environmental Health, Part B 18:1–42 doi:10.1080/10937404.2014.997945
   PubMed Web of Science ®Google Scholar
• Xio, S., D. Li, J. Vijg, D. J. Sugarbaker, J. M. Corson, and J. A. Fletcher. 1995. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511–15.
   PubMed Web of Science ®Google Scholar
• Xu, J., Y. Kadariya, M. Cheung, J. Pei, J. Talarchek, E. Sementino, Y. Tan, C. W. Menges, K. Q. Cai, S. Litwin, H. Peng, J. Karar, F. J. Rauscher, and J. R. Testa. 2014. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Research 74:4388–97. doi:10.1158/0008-5472.CAN-14-1328
   PubMed Web of Science ®Google Scholar
• Yoshikawa, Y., A. Sato, T. Tsujimura, M. Emi, T. Morinaga, K. Fukuoka, S. Yamada, A. Murakami, N. Kondo, S. Matsumoto, Y. Okumura, F. Tanaka, S. Hasegawa, T. Nakano, and T. Hashimoto-Tamaoki. 2012. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Science 103:868–74. doi:10.1111/cas.2012.103.issue-5
   PubMed Web of Science ®Google Scholar
• Zalcman, G., J. Mazieres, J. Margery, L. Greillier, C. Audigier-Valette, D. Moro-Sibilot, O. Molinier, R. Corre, I. Monnet, V. Gounant, F. Riviere, H. Janicot, R. Gervais, C. Locher, B. Milleron, Q. Tran, M. P. Lebitasy, F. Morin, C. Creveuil, J. J. Parienti, and A. Scherpereel, and Intergroup French Cooperative Thoracic. 2016. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet. 387:1405–14.
   PubMed Web of Science ®Google Scholar
• Zauderer, M. G., M. Bott, R. McMillan, C. S. Sima, V. Rusch, L. M. Krug, and M. Ladanyi. 2013. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. Journal of Thoracic Oncology 8:1430–33. doi:10.1097/JTO.0b013e31829e7ef9.
   PubMed Web of Science ®Google Scholar